118th Congress · SENATE BILLBILL

S. 1712Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2023

A bill to amend the Federal Food, Drug, and Cosmetic Act to provide for reciprocal marketing approval of certain drugs, biological products, and devices that are authorized to be lawfully marketed abroad, and for other purposes.

Health
Introduced May 18, 2023
Last action May 18, 2023
Pipeline · Bill → Law
Step 1
Introduced
May 18, 2023
Step 2
Referred
May 18, 2023
HELP
Step 3
Committee
Step 4
Senate
Step 5
House floor
Step 6
Resolve Changes
Step 7
Signed
SummaryCRS Summary

This bill establishes a reciprocal marketing approval process that allows for the sale of a drug, biological product, or medical device that has not been approved by the Food and Drug Administration (FDA) if the product is approved for sale in another country and there is an unmet need. Specifically, in order to receive reciprocal approval, the bill requires the product's sponsor to demonstrate, among other things, that (1) the product has been approved in one of the specified countries, (2) neither the FDA nor any of the specified countries have withdrawn approval for the product because of safety or effectiveness concerns, and (3) there is a public health or unmet medical need for the pro...

Provisions · 2 sectionsIntroduced in Senate
Timeline · 2 actions
May 18, 2023
Introduced in Senate
May 18, 2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.